Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry.
COVID-19
/ diagnosis
COVID-19 Testing
Comorbidity
Donor Selection
/ standards
Early Diagnosis
Europe
/ epidemiology
Health Care Surveys
Humans
Immunocompromised Host
Incidence
Liver Diseases
/ epidemiology
Liver Transplantation
/ statistics & numerical data
Mass Screening
Pandemics
Postoperative Complications
/ epidemiology
Procedures and Techniques Utilization
Registries
Risk
SARS-CoV-2
Tissue Donors
/ statistics & numerical data
Transplant Recipients
/ statistics & numerical data
COVID-19
SARS-CoV-2
liver recipient
liver transplantation
mortality
survey
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
10
05
2020
revised:
25
05
2020
accepted:
22
06
2020
pubmed:
2
7
2020
medline:
29
12
2020
entrez:
2
7
2020
Statut:
ppublish
Résumé
There are scarce data on the impact of COVID-19 pandemic on liver transplantation (LT) in Europe. The aim of this study was to obtain a preliminary data on incidence, management, and outcome of COVID-19 in liver transplant recipients and candidates in Europe. An Internet-based survey was sent to the centers affiliated with European Liver Transplant Registry (ELTR). One hundred nine out of 149 (73%) of ELTR centers located in 28 European countries (93%) responded. Ninety-four (86%) of the centers tested all donors, and 75 (69%) centers tested all LT recipients for SARS-CoV-2. Seventy-three (67%) centers selected recipients for LT in the COVID-19 pandemic, whereas 33% did not. Eighty-eight centers reported COVID-19 infection in 57 LT candidates and in 272 LT recipients. Overall crude incidence of COVID-19 among LT candidates and recipients was estimated 1.05% (range 0.5-20%) and 0.34% (range 0.1-4.8%), respectively, and it was significantly higher among candidates (P < 0.001). Crude rate of death was 18% (10/57) among candidates and 15% (36/244) among recipients. This first large-scale European snapshot study clearly shows that both LT candidates and recipients are at a high risk for COVID-19. These results plead for an early and pro-active screening of COVID-19 symptoms in these populations.
Identifiants
pubmed: 32609908
doi: 10.1111/tri.13680
pmc: PMC7361228
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1244-1252Subventions
Organisme : Astellas
Pays : International
Organisme : Novartis
Pays : International
Organisme : Institut Georges Lopez
Pays : International
Organisme : Sandoz
Pays : International
Organisme : Paul Brousse Hospital
Pays : International
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
Am J Transplant. 2020 Jul;20(7):1826-1836
pubmed: 32323460
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Transplant. 2020 Jul;20(7):1780-1784
pubmed: 32243677
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
J Heart Lung Transplant. 2020 Jun;39(6):610-611
pubmed: 32340870
Transpl Int. 2018 Dec;31(12):1293-1317
pubmed: 30259574
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Am J Transplant. 2020 Jul;20(7):1840-1848
pubmed: 32330351
Transpl Int. 2020 Aug;33(8):969-970
pubmed: 32348586
Hepatology. 2020 Jul;72(1):287-304
pubmed: 32298473
Am J Transplant. 2020 Sep;20(9):2593-2598
pubmed: 32359194
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366